Physician profile
Kathy E Bryant
NPI 1619277803
$7,823.72
in general payments reported to CMS, 2019-2025
24 companies · $2,133 in 2025
The $2,133 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $419 · 2022: $1,035 · 2023: $2,269 · 2024: $1,967 · 2025: $2,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,312 · Education: $57.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,311.88 |
| Education | $57.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,493.81 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,108.53 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $1,097.55 | 2022-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $814.17 | 2022-2025 | Spravato, Invega Sustenna, Invega |
| Axsome Therapeutics, INC. | $431.26 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $407.56 | 2021-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $392.37 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $371.67 | 2023-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $275.60 | 2023-2025 | Austedo Xr, Austedo Xr |
| Corium, LLC | $222.30 | 2022-2024 | Azstarys |
| Medline Industries LP | $184.39 | 2023-2024 | |
| Sunovion Pharmaceuticals INC. | $173.09 | 2021-2022 | |
| Harmony Biosciences LLC | $167.91 | 2024-2025 | |
| Lundbeck LLC | $133.58 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $122.12 | 2022-2025 | Qelbree, Qelbree |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tms Neurohealth Centers INC. | $97.28 | 2025 | Tms Neurohealth Centers INC. |
| Alkermes, INC. | $91.34 | 2022-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $58.52 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $55.29 | 2022-2023 | Quviviq |
| Almatica Pharma LLC | $53.61 | 2023-2024 | Loreev Xr, Teriparatide, Gralise |
| Tris Pharma INC | $27.30 | 2022-2024 | Dyanavel Xr |
| Avanir Pharmaceuticals, INC. | $16.84 | 2021 | |
| Neos Therapeutics, LP | $14.25 | 2024 | Adzenys Xr-Odt |
| United Therapeutics Corporation | $13.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathy Bryant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.